Updated on 5 September 2013
"Certain senior executives of GSK China who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law. We have zero tolerance for any behavior of this nature," Mr Hussain said.
A couple of days after this, while announcing the company's interim results, GSK CEO Sir (Dr) Andrew Witty reiterated the same things. "GSK's head office in London knew nothing of the fraud allegations until they were announced by the Chinese police," he argued. "The Chinese investigation appears to be focused on a number of senior managers, potentially defrauding GSK and doing something inappropriate and illegal. The allegations are shameful and deeply disappointing. To be crystal clear we have zero tolerance to this sort of behavior," he added.
On July 26, the company made a senior management change announcement. Senior vice president of Europe Mr Herve Gisserot took over as general manager from Mr Mark Reilly, who would now remain with the company as a senior member of the management team, the company spokesperson said.
Mr Gisserot's main role will be to ensure that GSK's China business continues to operate as smoothly as possible. Even the travel ban on Mr Nechelput was lifted. As this edition went in for print, the Chinese government released yet another statement claiming that other pharma giants were being probed closely and the evidence collection was currently on.
Also Read: Anti-corruption rules in China